News BioMarin snaps up Alesta's lead asset for $275m BioMarin will acquire Alesta's experimental therapy for rare bone disease hypophosphatasia for up to $490 million.
News Kardigan raises $300m for cardio work, and other financings Kardigan makes its debut with a teal of ex-MyoKardia execs and a $300m war chest, with a string of other biotechs also raising funds this week.
News Merck rare tumour drug Ezmekly backed for NHS use Merck's drug for tumours associated with rare disease neurofibromatosis type 1, Ezmekly, has been cleared for NHS use in children as young as two.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
